Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

doi:10.1158/1078-0432.CCR-09-0391

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2009

Morita Satoshi, Okamoto Isamu, Kobayashi Kunihiko, Yamazaki Koichi, Asahina Hajime, Inoue Akira, Hagiwara Koichi, Sunaga Noriaki, Yanagitani Noriko, Hida Toyoaki, Yoshida Kimihide, Hirashima Tomonori, Yasumoto Kosei, Sugio Kenji, Mitsudomi Tetsuya, Fukuoka Masahiro, Nukiwa Toshihiro

Abstract excerpt

PURPOSE: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are associated with an increased response to gefitinib in patients with non-small cell lung cancer. We have examined the impact of gefitinib on progression-free survival and overall survival in patients with EGFR mutation-positive non-small cell lung cancer. EXPERIMENTAL DESIGN: We searched for all clinical trials that prospectively...

Topics

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Clinical Trials, Phase II as Topic
Female
Gefitinib
Genes, erbB-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Humans

Lung Neoplasms

Male

Middle Aged

Mutation

Quinazolines

Survival Analysis

Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 19531624
DOI: 10.1158/1078-0432.CCR-09-0391

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-19531624-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.PMID 19531624Read ↗

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.Semantic proximity Read ↗

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.Semantic proximity Read ↗

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.Semantic proximity Read ↗

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.Semantic proximity Read ↗

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.Semantic proximity Read ↗

Gefitinib for non-small-cell lung cancer treatment.Semantic proximity Read ↗

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

Gefitinib for advanced non-small cell lung cancer.Semantic proximity Read ↗

The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.Semantic proximity Read ↗

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis.Semantic proximity Read ↗

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).Semantic proximity Read ↗

Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.